Cargando…

Mepolizumab and COPD in Real Life

Detalles Bibliográficos
Autores principales:	Revuelta-Salgado, Fernando, Díaz-Campos, Rocío Magdalena, Hernando-Sanz, Ascensión, Melero-Moreno, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369637/ https://www.ncbi.nlm.nih.gov/pubmed/37497168 http://dx.doi.org/10.1016/j.opresp.2021.100141

Ejemplares similares

Does Airway T2 Inflammation Increase the Severity of Bronchial Hyperresponsiveness?
por: Jiménez-Gómez, Miguel, et al.
Publicado: (2023)

Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series
por: Detoraki, Aikaterini, et al.
Publicado: (2021)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)

Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps
por: Domínguez-Sosa, María Sandra, et al.
Publicado: (2023)

Consensus on the Management of the COPD Patient in the COVID-19 Setting: COPD Forum Working Group
por: Calle Rubio, Myriam, et al.
Publicado: (2022)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Asthma and COPD in hospitalized COVID-19 patients()
por: García-Pachón, Eduardo, et al.
Publicado: (2020)

Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data
por: Nagase, Hiroyuki, et al.
Publicado: (2021)

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
por: Ortega, Hector, et al.
Publicado: (2019)

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Reduction in Hospital Admissions for COPD Exacerbation During the Covid-19 Pandemic
por: Baeza-Martínez, Carlos, et al.
Publicado: (2020)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

Do not do in COPD: consensus statement on overuse
por: Villar-Álvarez, Felipe, et al.
Publicado: (2018)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Clinical outcomes of using plasma in COVID-19 convalescent critically ill patients
por: Astola Hidalgo, I., et al.
Publicado: (2023)

Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
por: Azim, Adnan, et al.
Publicado: (2021)

Mepolizumab does not alter the blood basophil count in severe asthma
por: Wright, Adam Kelvin Alec, et al.
Publicado: (2019)

Surgical education during pandemic times: How the virtual world can help us in real life? The Hernia U experience
por: Malcher, Flavio, et al.
Publicado: (2021)

Reduction in Hospital Admissions for Asthma and COPD During the First Year of COVID-19 Pandemic in Spain
por: Galán-Negrillo, Marta, et al.
Publicado: (2023)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

Reduction in the incidence of acute bronchiolitis and related hospital admissions during the COVID-19 pandemic()
por: Montejo, Marta, et al.
Publicado: (2022)

Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis
por: Ulu, Kadir, et al.
Publicado: (2022)

Impact of the COVID 19 pandemic on new diagnoses of HIV infection
por: Galicia, Pilar, et al.
Publicado: (2023)

Impact of the COVID 19 pandemic on new diagnoses of HIV infection
por: Galicia, Pilar, et al.
Publicado: (2023)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Impact of gender on COPD expression in a real-life cohort
por: Roche, Nicolas, et al.
Publicado: (2014)

Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions
por: Molica, Stefano, et al.
Publicado: (2021)

Can a Telemedicine Program Reduce the Number of Admissions in the Second and Third Month After Hospital Discharge for an Exacerbation of COPD Compared to a Conventional Follow-up System?
por: Naya Prieto, Alba, et al.
Publicado: (2022)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

PCR test for SARS-CoV-2 persistently positive. Virus detection is not always COVID-19()
por: Herrero Hernando, Carlos, et al.
Publicado: (2020)

[Translated article] Decline of Tuberculosis Rates and COVID-19 Pandemic. Fact or Fiction?
por: Vázquez-Temprano, Nuria, et al.
Publicado: (2022)

The Width of Life Is More Important Than the Length of Life
por: Yakut, İdris, et al.
Publicado: (2023)

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
por: Llanos, Jean-Pierre, et al.
Publicado: (2020)

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
por: Prætorius, Katrine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqmt7qd21e8qka6f0tlq9denm1